【美台醫學研究合作新里程碑】

近年來肺癌及上呼吸道癌症病率不斷上升，為美國和台灣癌症死亡率最高的癌症。2019年美台簽署了肺癌及上呼吸道癌症研究的合作協定，由 #美國國家衛生研究院、#台北榮民總醫院 和 #國立陽明交通大學共同參與此項研究計畫，並在台灣建立了#史蒂芬索拉茲國際研究實驗室。

該合作突顯出東西方肺癌及上呼吸道癌症患者的差異，並加速開發診斷、治療和預防肺癌及上呼吸道惡性腫瘤的新方法。這些惡性腫瘤每年在全世界共造成200萬人死亡。臨床試驗即將在美國國家衛生研究院臨床中心與台北榮民總醫院同時展開。美國國家衛生研究院臨床中心是世界上從事醫學研究最大的專門醫院，台北榮民總醫院也是亞洲最大、最負盛名的醫院之一。

美國在台協會很高興於9月24日在見證了這個位於台北榮民總醫院的國際實驗室正式啟用。這類型的國際科學合作不僅將造福於人類，而且還提供訓練給肺癌及上呼吸道腫瘤醫學和轉化性癌症研究人員。

The number of people diagnosed with thoracic cancer has been increasing in recent years and its mortality rate is the highest in the United States and in Taiwan. In 2019, the United States and Taiwan signed an agreement to collaborate on thoracic cancer research and establish the Stephen J. Solarz International Research Laboratory in Taiwan. This international standard laboratory will conduct research to characterize distinct features that cause thoracic cancers in Asian versus Caucasian patients and accelerate the development of novel methods to diagnose, treat, and prevent thoracic malignancies that collectively account for two million deaths a year worldwide. Clinical trials will begin simultaneously at the U.S. National Institute of Health Clinical Center, the largest hospital in the world dedicated solely to medical research, and Taipei Veterans General Hospital (TVGH), one of the largest and most prestigious hospitals in Asia, in the near future. On Friday, AIT Economic Officer Neevy Laningham participated virtually in a ceremony to launch the Stephen J. Solarz International Research Laboratory, located in TVGH. This U.S.-Taiwan collaboration will not only benefit patients but will also provide training to future researchers in thoracic oncology and translational cancer.

Just reposting some evidence-based guidelines which commentators will probably turn a blind eye to anyway

#3832
"To reporters of Apple Daily, please read the guidelines/studies before commenting that the doctor in-charge made a mistake

From uptodate.com

- In a meta-analysis of randomized trials of PCP prophylaxis in immunocompromised patients without HIV infection, the authors concluded that prophylaxis is warranted when the risk of PCP is higher than 6 percent
- Patients receiving a glucocorticoid dose equivalent to ≥20 mg of prednisone daily for one month or longer who also have another cause of immunocompromise (eg, certain hematologic malignancies or a second immunosuppressive drug)

If we follow the guideline/literature, this patient does NOT need PCP prophylaxis
(Although PCP prophylaxis can be considered, after assessing the risks and benefits)
There is no hard and fast rule on PCP/anti-fungal/TB prophylaxis and all decisions need to be made on individual basis
If the case is considered to have low risk, it is reasonable not to prescribe steroid
There is no good evidence on PCP prophylaxis for patients on single immunosuppressant

https://hk.news.appledaily.com/…/…/article/20171103/20203088"

常用藥飆漲 最高逾2倍 （www.worldjournal.com/3883062/article-常用藥飆漲-最高逾2倍/）

目前西醫廠賣出的治療關節炎、高膽固醇、氣喘等等藥物，根本沒用辦法解決問題，充其量只是在壓制現象，讓病人感覺好一些，卻帶來很多副作用。譬如關節炎藥Humira，我們不需要看FDA檔案中詳細的內容，只需要查一下一般醫學網站，就可以有個基本的概念，http://如www.drugs.com/sfx/humira-side-effects.html就直接寫著："The most serious adverse reactions have been serious infections, neurologic events, and malignancies."（最嚴重的副作用包括嚴重感染、神經系統問題、惡性腫瘤），寫給醫療人員的副作用資料一長串，留給讀者自己去查看，下面是寫給一般人(consumers)看的，服用Humira後可能有的問題：

Abdominal or stomach fullness...
Continue Reading